Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis

Orthopedics. 2006 Jun;29(6):497-501. doi: 10.3928/01477447-20060601-11.
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / therapeutic use
  • Clindamycin / pharmacokinetics
  • Clindamycin / therapeutic use
  • Humans
  • Methicillin Resistance*
  • Osteomyelitis / drug therapy*
  • Osteomyelitis / microbiology
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus
  • Tetracycline / pharmacokinetics
  • Tetracycline / therapeutic use
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacokinetics
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Vancomycin / pharmacokinetics
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Clindamycin
  • Vancomycin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Tetracycline